Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. (PROTEUS)

NCT01941329 is registered in ClinicalTrials.gov with Association for Innovation and Biomedical Research on Light and Image as lead sponsor.

NCT NCT01941329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01941329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. (PROTEUS)
Lead sponsor
Association for Innovation and Biomedical Research on Light and Image
Phase
Phase 2/3
Overall status
Completed
Start date
April 30, 2014
Completion date
October 31, 2017
Enrollment
94 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

high risk proliferative diabetic retinopathy